Biotech’s IPO pipeline stayed hot with oversubscribed debuts from newly public companies including Latigo Biotherapeutics and Blossomhill Therapeutics. Latigo priced an IPO to raise about $345.6 million to advance a non-opioid Nav1.8 pain pipeline, leveraging ion-channel biology to target pain without opioid dependence. Blossomhill’s $150 million offering funded next-generation macrocyclic inhibitors aimed at oncology targets including EGFR-mutant non-small-cell lung cancer, as the company upsized from its original share count and priced at the low end. Together, the transactions add to a late-2026 theme of larger-than-proposed biotech offerings to secure runway for clinical execution. For investors and developers, the listings highlight both continued appetite for differentiated mechanism-of-action assets and an emphasis on pipeline clarity at pricing.